Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study

BACKGROUND: Survival outcomes for patients with glioblastoma remain poor, particularly for patients with unmethylated O(6)-methylguanine-DNA methyltransferase (MGMT) gene promoter. This phase II, randomized, open-label, multicenter trial investigated the efficacy and safety of 2 dose regimens of the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Nabors, L. Burt, Fink, Karen L., Mikkelsen, Tom, Grujicic, Danica, Tarnawski, Rafal, Nam, Do Hyun, Mazurkiewicz, Maria, Salacz, Michael, Ashby, Lynn, Zagonel, Vittorina, Depenni, Roberta, Perry, James R., Hicking, Christine, Picard, Martin, Hegi, Monika E., Lhermitte, Benoit, Reardon, David A.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2015
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4482861/
https://ncbi.nlm.nih.gov/pubmed/25762461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou356
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados